Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
์ข
๋ชฉ ์ฝ๋ GCTK
ํ์ฌ ์ด๋ฆGlucoTrack Inc
์์ฅ์ผApr 09, 2013
CEOGoode (Paul V)
์ง์ ์11
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃApr 09
์ฃผ์301 Rt 17 North
๋์RUTHERFORD
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ07070
์ ํ197286757878
์น์ฌ์ดํธhttps://glucotrack.com/
์ข
๋ชฉ ์ฝ๋ GCTK
์์ฅ์ผApr 09, 2013
CEOGoode (Paul V)